{"organizations": [], "uuid": "a9fd751ab9751d9c9684a2db76c7ad6bb32ba152", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-helix-biopharma-signs-binding-lett/brief-helix-biopharma-signs-binding-letter-of-intent-for-development-of-new-car-t-technologies-idUSFWN1OZ0YY", "country": "US", "domain_rank": 408, "title": "BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T00:54:00.000+02:00", "replies_count": 0, "uuid": "a9fd751ab9751d9c9684a2db76c7ad6bb32ba152"}, "author": "", "url": "https://www.reuters.com/article/brief-helix-biopharma-signs-binding-lett/brief-helix-biopharma-signs-binding-letter-of-intent-for-development-of-new-car-t-technologies-idUSFWN1OZ0YY", "ord_in_thread": 0, "title": "BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-helix biopharma signs binding letter of int", "sentiment": "negative"}, {"name": "brief-helix biopharma signs binding letter of intent for development of new car-t technologies", "sentiment": "negative"}, {"name": "development of new car-t technologies reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "helix biopharma corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "biopharma corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 10:55 PM / Updated 7 minutes ago BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies Reuters Staff \nJan 4 (Reuters) - Helix Biopharma Corp: \n* HELIX BIOPHARMA CORP. SIGNS BINDING LETTER OF INTENT FOR DEVELOPMENT OF NEW CAR-T TECHNOLOGIES \n* SAYS‍ IMMEDIATE FOCUS WILL INVOLVE PRECLINICAL WORK IN SUPPORT OF A NEW IND APPLICATION OF A CAR-T FOR HEMATOLOGICAL MALIGNANCIES​ \n* SAYS ‍FINALIZATION OF COLLABORATIVE BINDING LOI WITH PROMAB BIOTECHNOLOGIES TO DEVELOP CHIMERIC ANTIGEN RECEPTOR CAR-T FOR HEMATOLOGICAL MALIGNANCES AND SOLID TUMOURS​ \n* SAYS UNDER AGREEMENT,CO RETAINS EXCLUSIVE LICENSE FOR COMMERCIALIZATION OF PRODUCT CANDIDATES DEVELOPED ALONE OR IN COMBINATION WITH DOS47​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T00:54:00.000+02:00", "crawled": "2018-01-05T01:11:51.000+02:00", "highlightTitle": ""}